The initiation of highly active antiretroviral therapy (HAART) plays a significant role in the clinical management of HIV infected people by preventing morbidity and mortality. This benefit becomes, the most terrible when treatment failure develops. Thus, this research aims to assess the prevalence and associated factors of treatment failure among HIV/AIDS patients on HAART attending University of Gondar Referral Hospital Northwest Ethiopia. Patients on ART with a minimum of 6 months and up to 12 years of treatment were being enrolled. The prevalence of treatment failure, immunological failure and virological failure among people living with HIV/AIDS attending University of Gondar referral hospital were 20.3, 13.2, and 14.7%, respectively. Patients who had no formal education (Adjusted odds ratio (AOR): 3.8; 95% CI, 1.05–13.77), primary level education (AOR: 4.2; 95% CI, 1.16–15.01) and duration on ART < 6 years (AOR: 2.1; 95%CI, 1.12–3.81) were a significant risk factor. However, initial adult regimen D4T +  3TC+ EFV (AOR: 0.025; 95% CI, 0.002–0.36), AZT +3TC + NVP (AOR: 0.07; 95% CI, 0.01–0.71), AZT +  3TC + EFV (AOR: 0.046; 95% CI, 0.004–0.57) andTDF+3TC + EFV (AOR: 0.04; 95% CI, 0.004–0.46) were significantly protective for treatment failure. Timely and early identification of associated factors and monitoring antiretroviral therapy treatment failure should be done to enhance the benefit and to prevent further complication of the patients. It is preferable to initiate ART using any one of the following ART regimens: AZT +3TC + NVP, AZT + 3TC + EFV and TDF + 3TC + EFV to prevent treatment failure. Since the prevalence of this treatment failure and its associated factor may be different from other ART centers and community in Ethiopia, further national representative institutional based cross-sectional researches are needed across all ART centers of Ethiopia in order to determine the prevalence of treatment failure and its associated factors.

中文翻译：

---

埃塞俄比亚西北部贡德尔大学转诊医院的HAART上HIV / AIDS患者的治疗失败率及其相关因素

通过预防发病率和死亡率，高活性抗逆转录病毒疗法（HAART）的启动在HIV感染者的临床管理中起着重要作用。当治疗失败发生时，这种益处变得最可怕。因此，本研究旨在评估在埃塞俄比亚西北部冈达尔大学转诊医院就读的HAART上HIV / AIDS患者的治疗失败率及其相关因素。接受ART治疗且病程最少为6个月且最长为12年的患者。在贡达尔大学转诊医院的艾滋病毒/艾滋病感染者中，治疗失败，免疫学失败和病毒学失败的发生率分别为20.3、13.2和14.7％。没有接受正规教育的患者（校正比值比（AOR）：3.8； 95％CI，1.05–13.77），初级教育（AOR：4.2; 95％CI，1.16–15.01）和ART ＜6年的持续时间（AOR：2.1; 95％CI，1.12–3.81）是重要的危险因素。但是，初始成人方案D4T + 3TC + EFV（AOR：0.025; 95％CI，0.002-0.36），AZT + 3TC + NVP（AOR：0.07; 95％CI，0.01-0.71），AZT + 3TC + EFV（AOR： 0.046； 95％CI，0.004-0.57）和TDF + 3TC + EFV（AOR：0.04； 95％CI，0.004-0.46）对治疗失败具有明显的保护作用。应及早及早发现相关因素并监测抗逆转录病毒疗法的治疗失败，以提高疗效并防止患者进一步并发症。为防止治疗失败，最好使用以下任何一种ART方案启动ART：AZT + 3TC + NVP，AZT + 3TC + EFV和TDF + 3TC + EFV。